Status: Recruiting
Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk
The Low dose ColchicinE in pAtients with peripheral Artery DiseasE to address residual vascular Risk (LEADER-PAD) trial will evaluate if anti-inflammatory therapy with colchicine will reduce vascular events in patients with symptomatic peripheral artery disease.
Participants needed: 6,150
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Population Health Research InstituteUpdated: Mar 24, 2026Locations: 70
Eligibility criteria
Age > 18 years [+1]
Contraindication to colchicine [+8]